Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018

Author's Avatar
Apr 09, 2018
Article's Main Image

First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia

Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time

New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176

PR Newswire